SEC Form 4 · accession 0001209191-19-009704
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Howard Levy
Officer — Chief Medical Officer
Period of report
Feb 11, 2019
Accepted (ET)
Feb 13, 2019 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 11, 2019 | A | 2,485 | $7.04 | A | 11,867 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares purchased under the Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan ("ESPP") on February 11, 2019.